Results 211 to 220 of about 73,738 (335)

Isolation of neutralizing antibodies against SARS-CoV-2 through an epitope-guided negative screening by phage display. [PDF]

J Biomed Res
Lu M, Chen Y, Liu X, Gao F, Gou L, Ye W, Wen J, Guo X, Gao W.   +8 more
europepmc   +1 more source

Designing Human Antibodies by Phage Display

Transfusion Medicine and Hemotherapy, 2017
A. Frenzel, J. Kügler, Saskia Helmsing, D. Meier, T. Schirrmann, M. Hust, S. Dübel   +6 more
semanticscholar   +1 more source

Diet–Microbiome–Immune Interactions at the Gut Mucosa in Food Allergy: Mechanisms, Gaps, and Therapeutic Implications

Allergy, EarlyView.
ABSTRACT Mucosal surfaces are sites of highly dynamic interactions among epithelial and immune cells, environmental exposures, particularly dietary inputs, and the diverse microbial communities and their metabolites. These elements continually influence each other to maintain homeostasis and ensure appropriate immune discrimination between pathogens ...
Clara Delaroque, Liam O'Mahony, Inge Kortekaas Krohn, Charlotte G. Mortz, Markus Ollert, Mahesh S. Desai   +5 more
wiley   +1 more source

Identification of novel serum biomarkers for Alzheimer's disease screened by phage display library of random peptides. [PDF]

J Alzheimers Dis Rep
Gao D, Han Z, Ai X, Wang F, Lai D, Gao C, Zhang Z, Tao S, Shang J, Zhang J.   +9 more
europepmc   +1 more source

Advances in the T7 phage display system (Review).

Molecular Medicine Reports, 2017
Xiangying Deng, Li Wang, Xiaolong You, Pei Dai, Yanhua Zeng   +4 more
semanticscholar   +1 more source

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz, Sophie Sprenger, Olga Schweigert, Sanika Mohagaonkar, Matti Walsdorff, Tanja Zeller, Filip Berisha, Viacheslav O. Nikolaev, Sergei D. Rybalkin   +8 more
wiley   +1 more source

Using phage display for rational engineering of a higher-affinity humanized 3' phosphohistidine-specific antibody. [PDF]

Commun Chem
Martyn GD, Kalagiri R, Veggiani G, Stanfield RL, Choudhuri I, Sala M, Meisenhelder J, Chen C, Biswas A, Levy RM, Lyumkis D, Wilson IA, Hunter T, Sidhu SS.   +13 more
europepmc   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Macrocyclic Phage Display for Identification of Selective Protease Substrates. [PDF]

J Am Chem Soc
Faucher FF, Blažková K, Lovell S, Bertolini M, Herrero-Bourdieu J, Cosco ED, Bogyo M, Barniol-Xicota M.   +7 more
europepmc   +1 more source

Multivalent antibody‐based conjugates as new tools for tailored modulation of G protein–coupled receptors

British Journal of Pharmacology, EarlyView.
The G protein–coupled receptor (GPCR) superfamily consists of the most common targets of approved drugs. Targeting GPCRs offers appealing avenues for therapeutic development. Antibodies and their fragments, such as single‐domain antibodies (VHHs or nanobodies), have emerged as useful alternatives to small molecule pharmacophores as building blocks in ...
Shivani Sachdev, Ross W. Cheloha
wiley   +1 more source